Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for establishing hyperuricemia animal model and application thereof

An animal model and composition technology, which is applied in the directions of active ingredients of heterocyclic compounds, medical preparations containing active ingredients, and pharmaceutical formulations, can solve problems such as large gaps and inconvenient feeding, and achieves short modeling time and modeling. Reasonable method and high modeling success rate

Active Publication Date: 2014-06-18
四川普莱美行之生物科技有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has something in common with humans in terms of uric acid synthesis and metabolism: but there is a large gap with humans in terms of species, and it is not convenient to raise in ordinary laboratories

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for establishing hyperuricemia animal model and application thereof
  • Medicinal composition for establishing hyperuricemia animal model and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] A pharmaceutical composition for establishing an animal model of hyperuricemia, the pharmaceutical composition consists of 5 parts of ethambutol and 5 parts of uric acid in parts by weight. The modeling time required by using the pharmaceutical composition is short, a stable model can be obtained after 3 days of administration, and the success rate of modeling is high.

Embodiment 2

[0027] A pharmaceutical composition for establishing an animal model of hyperuricemia, the pharmaceutical composition consists of 1 part of ethambutol and 2 parts of uric acid in parts by weight. The required modeling time is short, a stable model can be obtained after 7 days of administration, and the success rate of modeling is high.

Embodiment 3

[0029] A pharmaceutical composition for establishing an animal model of hyperuricemia, the pharmaceutical composition consists of 4 parts by weight of ethambutol and 3 parts of uric acid. The required modeling time is short, a stable model can be obtained after 7 days of administration, and the success rate of modeling is high.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal composition for establishing a hyperuricemia animal model and an application thereof. The medicinal composition comprises ethambutol and uric acid, and can be used for preparing an acute hyperuricemia model with short modeling time, stable model and high modeling success rate. The medicinal composition is administrated to a rhesus monkey in an intragastric manner, a stable and reliable acute hyperuricemia model can be quickly obtained, and the modeling method is reasonable and close to the pathogenesis of human beings.

Description

technical field [0001] The invention belongs to the field of biology, and relates to a pharmaceutical composition for establishing an animal model of hyperuricemia and its application. technical background [0002] Hyperuricemia refers to a state of the body in which the concentration of uric acid in the blood exceeds the normal range. Hyperuricemia is the most important biochemical basis of gout, prone to gouty arthritis, tophi deposition and joint deformity. Gout is a group of heterogeneous diseases caused by purine metabolism disorder and decreased excretion of uric acid, clinically characterized by hyperuricemia. [0003] In the human uric acid metabolism pathway, uric acid is the end product of human purine metabolism. There are two sources of uric acid in the human body, uric acid is synthesized in the body, or uric acid is produced by nucleic acid decomposition (endogenous), accounting for about 80% of the total uric acid in the body. Purine or nucleotides in food a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/522A61K31/133A01K67/027
Inventor 曾文龚立曾利才潘玲珍
Owner 四川普莱美行之生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products